A combined, tailored pharmacist intervention with dose optimization of phosphate binding drugs to improve phosphate control in patients on dialysis.
- Conditions
- Chronic kidney disease, end-stage renal disease, hemodialysis, hyperphosphatemia
- Registration Number
- NL-OMON24286
- Lead Sponsor
- Franciscus Gasthuis and Vlietland
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 45
Inclusion Criteria
Both the mean serum phosphate level over the last 3 months and the last serum phosphate level are higher than 1.5 mmol/L.
-Prescription for 6 or more phosphate binder units daily
- Age of 18 years or older
-Medication dispensed by Poli-apotheek Franciscus Gasthuis
-Intermittent hemodialysis for at least 3 months preceding the inclusion date.
-Hemodialysis during entire follow-up
-Sufficient language proficiency to comprehend instructions concerning study procedures, such as informed consent.
Exclusion Criteria
-Patients residing in a nursing home
-Cognitive impairment, resulting in failure to comprehend instructions concerning study procedures.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome variable is the difference between the mean serum phosphate level over the 3 months before the intervention, and the mean serum phosphate level over the first 3 months after the intervention.
- Secondary Outcome Measures
Name Time Method •the percentage of patients with a mean serum phosphate level of 1.5 mmol/L or lower, measured the 3 months before and 3, 6 and 12 months after the intervention. <br>•the trend in serum phosphate level during follow-up <br>•the difference between the mean serum phosphate level over the 3 months before the intervention, and the serum phosphate level at 6 and 12 months after the intervention<br>•the implementation fidelity of the intervention, including barriers and facilitators for implementation<br>•pharmaceutical literacy <br>•medication adherence (MARS-5) before and after the intervention<br>